BPC-157 hasn't been approved by the FDA. But that hasn't stopped this buzzy drug from gaining traction – and attention from MAHA.

The gray market is awash with BPC-157, a drug hyped as a cure-all, but unapproved by the FDA. Will RFK Jr. change that?

An informational overview of reported February 2026 developments, FDA-approved vs. compounded medication distinctions, Wegovy pill category context, published pricing disclosures, telehealth ...

Debated is the genesis of the first direct-to-consumer (DTC) drug concept in the U.S. Going back to at least 2011, Pfizer’s “unorthodox” ...

Carefully timed bursts of carbon dioxide are emerging as a surprising tool to help the brain wash away toxic proteins linked to Parkinson’s disease. Instead of a new pill or implant, researchers are ...

Albert Bourla: 2025 was a very good year for Pfizer Inc. I'm very pleased with strong execution to deliver and, frankly, overdeliver on our financial commitments. If successful, we will substantially ...

Good day, everyone, and welcome to Pfizer's Fourth Quarter 2025 Earnings Conference Call. Today's call is being recorded. At ...

Shareholder/Analyst Call February 5, 2026 3:30 PM ESTCompany ParticipantsRyan Watts - Co-Founder, President, CEO ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Thomas J. Brock is a CFA and CPA with more than 20 years of experience in various areas including investing, ...

Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Eric's career includes extensive work in ...

These versatile strategies—from brain dumps to speed sharing—help students track their own progress while informing your next instructional steps.

At Healthline, we’re committed to providing you with trustworthy, accessible, and accurate information so you’re equipped to care for your health and wellness. We use an established Editorial Process ...